Robert M Grant

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Accuracy of the TRUGENE HIV-1 genotyping kit
    Robert M Grant
    Gladstone Institute of Virology and Immunology, San Francisco, CA 94141, USA
    J Clin Microbiol 41:1586-93. 2003
  2. ncbi request reprint AIDS. Promote HIV chemoprophylaxis research, don't prevent it
    Robert M Grant
    Gladstone Institute of Virology and Immunology, San Francisco, CA, USA
    Science 309:2170-1. 2005
  3. ncbi request reprint Time trends in primary HIV-1 drug resistance among recently infected persons
    Robert M Grant
    Gladstone Institute of Virology and Immunology, PO Box 914100, San Francisco, CA 94141, USA
    JAMA 288:181-8. 2002
  4. ncbi request reprint Persistence of primary drug resistance among recently HIV-1 infected adults
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, San Francisco, California 94141 9100, USA
    AIDS 18:1683-9. 2004
  5. ncbi request reprint Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response
    Steven G Deeks
    University of California San Francisco and San Francisco General Hospital, 995 Potrero Avenue, San Francisco, CA 94110, USA
    AIDS 17:361-70. 2003
  6. ncbi request reprint Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, USA
    J Infect Dis 190:251-6. 2004
  7. pmc Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus
    Christian B Willberg
    Division of Experimental Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA
    PLoS Pathog 4:e1000185. 2008
  8. pmc Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, Department of Medicine, University of California, San Francisco, California, USA
    J Virol 76:11104-12. 2002
  9. ncbi request reprint Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection
    Steven G Deeks
    University of California, San Francisco, and San Francisco General Hospital, San Francisco 94110, USA
    J Infect Dis 192:1537-44. 2005
  10. ncbi request reprint T-cell activation and memory phenotypes in cerebrospinal fluid during HIV infection
    Jutta K Neuenburg
    Department of Neurology, San Francisco General Hospital, General Clinical Research Center at the University of California, San Francisco, CA 94158, USA
    J Acquir Immune Defic Syndr 39:16-22. 2005

Detail Information

Publications62

  1. pmc Accuracy of the TRUGENE HIV-1 genotyping kit
    Robert M Grant
    Gladstone Institute of Virology and Immunology, San Francisco, CA 94141, USA
    J Clin Microbiol 41:1586-93. 2003
    ..This integrated assay system for the detection of HIV-1 drug resistance mutations has a high degree of accuracy and reproducibility in several laboratories...
  2. ncbi request reprint AIDS. Promote HIV chemoprophylaxis research, don't prevent it
    Robert M Grant
    Gladstone Institute of Virology and Immunology, San Francisco, CA, USA
    Science 309:2170-1. 2005
  3. ncbi request reprint Time trends in primary HIV-1 drug resistance among recently infected persons
    Robert M Grant
    Gladstone Institute of Virology and Immunology, PO Box 914100, San Francisco, CA 94141, USA
    JAMA 288:181-8. 2002
    ..Transmission of multiclass drug-resistant human immunodeficiency virus type 1 (HIV-1) may increase with wider use of antiretroviral therapy...
  4. ncbi request reprint Persistence of primary drug resistance among recently HIV-1 infected adults
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, San Francisco, California 94141 9100, USA
    AIDS 18:1683-9. 2004
    ..We sought to determine if primary drug resistance would be lost at a rapid rate, and viral pol replication capacity would increase, in the absence of treatment...
  5. ncbi request reprint Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response
    Steven G Deeks
    University of California San Francisco and San Francisco General Hospital, 995 Potrero Avenue, San Francisco, CA 94110, USA
    AIDS 17:361-70. 2003
    ..We therefore studied the long-term treatment outcome to antiretroviral therapy in a cohort of patients who had previously interrupted therapy, focusing on the determinants of treatment success versus failure...
  6. ncbi request reprint Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, USA
    J Infect Dis 190:251-6. 2004
    ....
  7. pmc Immunity to HIV-1 is influenced by continued natural exposure to exogenous virus
    Christian B Willberg
    Division of Experimental Medicine, Department of Medicine, University of California San Francisco, San Francisco, California, USA
    PLoS Pathog 4:e1000185. 2008
    ..Continued sexual exposure to exogenous HIV-1 was associated with increased HIV-1-specific T cell responses, in the absence of systemic super-infection, and correlated with the level and type of exposure...
  8. pmc Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, Department of Medicine, University of California, San Francisco, California, USA
    J Virol 76:11104-12. 2002
    ....
  9. ncbi request reprint Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection
    Steven G Deeks
    University of California, San Francisco, and San Francisco General Hospital, San Francisco 94110, USA
    J Infect Dis 192:1537-44. 2005
    ..We hypothesized that the use of simplified regimens could maintain treatment benefit while preventing viral evolution and reducing drug-related toxicity and costs...
  10. ncbi request reprint T-cell activation and memory phenotypes in cerebrospinal fluid during HIV infection
    Jutta K Neuenburg
    Department of Neurology, San Francisco General Hospital, General Clinical Research Center at the University of California, San Francisco, CA 94158, USA
    J Acquir Immune Defic Syndr 39:16-22. 2005
    ..In HIV-infection, activated CD4+ and CD8+ T cells in CSF were more abundant than in uninfected controls. As expected, combination antiretroviral therapy (ART) reduced T cell activation in CSF and blood...
  11. pmc HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial
    Susan P Buchbinder
    Bridge HIV, San Francisco Department of Public Health, San Francisco, CA, USA Department of Medicine, University of California, San Francisco, CA, USA Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA Electronic address
    Lancet Infect Dis 14:468-75. 2014
    ..We aimed to estimate the PAF and NNT of participants in the iPrEx (Pre-Exposure Prophylaxis Initiative) trial...
  12. ncbi request reprint HIV-producing T cells in cerebrospinal fluid
    Jutta K Neuenburg
    Gladstone Institute of Virology and Immunology, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 37:1237-44. 2004
    ..In HIV-1 infection, CSF white cell counts seem to contain a large number of uninfected cells. White cell counts and viral load in CSF may result from systemic inflammation and immune activation...
  13. ncbi request reprint High-risk sexual behavior in adults with genotypically proven antiretroviral-resistant HIV infection
    Peter V Chin-Hong
    Department of Medicine, University of California at San Francisco and San Francisco General Hospital, San Francisco, CA, USA
    J Acquir Immune Defic Syndr 40:463-71. 2005
    ..Although there is an increasing emphasis on understanding high-risk behavior among HIV-infected patients, little work has focused on those with drug-resistant virus...
  14. ncbi request reprint Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity
    Jason D Barbour
    Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA
    AIDS 20:2123-5. 2006
    ..Viral polRC was measured before starting ART in all subjects. We examined 243 individuals for a median 260 days after initiating ART. Low baseline polRC was associated with greater CD4 T-cell gains independent of virological responses...
  15. pmc Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene
    Annika C Karlsson
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94141, USA
    J Virol 77:6743-52. 2003
    ..Our results indicate that both HIV type 1-specific CD8(+) T cells and antiretroviral drugs provide complex pressures on the same amino acid sequence of the HIV protease gene and, thus, can influence viral sequence evolution...
  16. ncbi request reprint Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy
    Jutta K Neuenburg
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94158, USA
    AIDS 19:1351-9. 2005
    ..Although clinical brain disease is uncommon during combination antiretroviral therapy (ART), autopsy series indicate that HIV-infected brain tissue can contain high numbers of monocytes/macrophages despite ART...
  17. pmc Changes in seroadaptive practices from before to after diagnosis of recent HIV infection among men who have sex with men
    Snigdha Vallabhaneni
    Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, CA, USA
    PLoS ONE 8:e55397. 2013
    ..We assessed changes in sexual behavior among men who have sex with men (MSM), before and for several years after HIV diagnosis, accounting for adoption of a variety of seroadaptive practices...
  18. pmc Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    Robert M Grant
    J David Gladstone Institutes, University of California at San Francisco, 1650 Owens St, San Francisco, CA 94158, USA
    N Engl J Med 363:2587-99. 2010
    ..Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition...
  19. ncbi request reprint CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy
    Steven G Deeks
    Department of Medicine, University of California at San Francisco and San Francisco General Hospital, San Francisco, CA 94110, USA
    J Infect Dis 185:315-23. 2002
    ..These data indicate that partial virus suppression reduces CD4(+) cell turnover and activation, thereby resulting in sustained CD4(+) cell gains, and that measurements of T cell dynamics may provide an in vivo marker of viral virulence...
  20. pmc Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men
    Julia L Marcus
    Gladstone Institute of Virology and Immunology, San Francisco, California, United States or America University of California, Berkeley, California, United States of America
    PLoS ONE 9:e91513. 2014
    ..We examined the effect of daily oral emtricitabine/tenofovir (FTC/TDF) PrEP on HSV-2 seroincidence and ulcer occurrence among men who have sex with men (MSM) in the iPrEx trial...
  21. doi request reprint Frequent international travel by men who have sex with men recently diagnosed with HIV-1: potential for transmission of primary HIV-1 drug resistance
    Hong M Truong
    Center for AIDS Prevention Studies, University of California, San Francisco, 50 Beale Street, Suite 1300, San Francisco, CA 94105, USA
    J Travel Med 15:454-6. 2008
    ..Given the high frequency of international travel and prevalence of primary HIV-1 drug resistance among study participants, prevention strategies should incorporate specific counseling on risk of cross-border transmission...
  22. ncbi request reprint Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study
    Donald I Abrams
    Community Consortium, Positive Health Program, University of California, San Francisco, CA 94143, USA
    AIDS Res Hum Retroviruses 23:77-85. 2007
    ....
  23. ncbi request reprint Research in situ
    Robert M Grant
    J David Gladstone Institutes and University of California San Francisco, San Francisco, California 94158, USA
    Nat Methods 4:887-90. 2007
  24. ncbi request reprint Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance
    Hong Ha M Truong
    University of California San Francisco, 50 Beale Street, San Francisco, CA 94105, USA
    AIDS 20:2193-7. 2006
    ..To estimate the rate of acute and recent HIV infections and the prevalence of primary antiretroviral resistance...
  25. ncbi request reprint The role of viral fitness in HIV pathogenesis
    Jason D Barbour
    Gladstone Institute of Virology and Immunology, 1650 Owens Street, San Francisco, CA 94158, USA
    Curr HIV/AIDS Rep 2:29-34. 2005
    ..The biological basis for elevated CD4+ T-cell counts among those carrying a virus of low pol RC may be because of lowered virus infectivity, or restricted tissue replication...
  26. pmc Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1
    Khaoula Bourara
    Gladstone Institute of Virology and Immunology, University of California San Francisco, San Francisco, California, USA
    PLoS Pathog 3:1477-85. 2007
    ..Developing drugs that inhibit A3C may be a novel strategy for delaying viral escape from immune or antiretroviral inhibition...
  27. pmc Whither or wither microbicides?
    Robert M Grant
    J David Gladstone Institutes, University of California San Francisco, San Francisco, CA 94518, USA
    Science 321:532-4. 2008
    ....
  28. ncbi request reprint Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells
    Kim S Stopak
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94158, USA
    J Biol Chem 282:3539-46. 2007
    ..Together, these results highlight the distinct inductive effects of select cytokines on A3G gene expression and A3G complex assembly that occur in natural cellular targets of HIV infection...
  29. pmc Decline in HIV infectivity following the introduction of highly active antiretroviral therapy
    Travis C Porco
    San Francisco Department of Public Health, Community Health and Epidemiology Section, San Francisco, CA, USA
    AIDS 18:81-8. 2004
    ..We estimated the degree to which the probability of HIV infection from an infected partner (the infectivity) declined following the introduction of highly active antiretroviral therapy (HAART) in San Francisco...
  30. pmc Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure
    Rose Tsui
    Blood Systems Research Institute, University of California, San Francisco, San Francisco, California, USA
    J Virol 78:94-103. 2004
    ..00, 0.79; P = 0.02), indicating that existing infection conferred a statistically significant level of protection against superinfection with an HIV-1 strain of the same subtype, which was between 21 and 100%...
  31. pmc Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
    Marc M Solomon
    aThe Gladstone Institutes bUniversity of California cBridge HIV, San Francisco Department of Public Health, San Francisco, USA dInvestigaciones Medicas en Salud eAsociación Civil Impacta Salud y Educación, Lima, Peru fInstituto de Pesquisa Clinica Evandro Chagas, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil gFenway Institute, Fenway Health, Boston, USA hResearch Institute for Health Sciences iDepartment of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand jProjeto Praça Onze, Hospital Escola Sao Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil kDesmond Tutu HIV Centre and Department of Medicine, University of Cape Town, Cape Town, South Africa lDivision of Clinical Immunology and Allergy, School of Medicine, University of São Paulo mInstituto de Investigação em Imunologia, CEP 05403 900 Cerqueira Cesar, Sao Paulo, Brazil nNational Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
    AIDS 28:851-9. 2014
    ..Tenofovir disoproxil fumarate (TDF) pre-exposure prophylaxis decreases sexual acquisition of HIV infection. We sought to evaluate the renal safety of TDF in HIV-uninfected persons...
  32. ncbi request reprint Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions
    Becky Schweighardt
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA, USA
    AIDS 16:2342-4. 2002
    ..We concluded that the repeated abrupt termination and resumption of certain antiretroviral drug regimens during STI therapy may lead to the development of drug resistance in chronically HIV-infected individuals...
  33. pmc Sexual seroadaptation: lessons for prevention and sex research from a cohort of HIV-positive men who have sex with men
    J Jeff McConnell
    Gladstone Institute of Virology and Immunology, San Francisco, California, United States of America
    PLoS ONE 5:e8831. 2010
    ..However, such analyses can be confounded by "seroadaptation"--the restriction of unprotected anal intercourse (UAI), especially unprotected insertive UAI, to seroconcordant partnerships...
  34. pmc Differential persistence of transmitted HIV-1 drug resistance mutation classes
    Vivek Jain
    HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA 94143, USA
    J Infect Dis 203:1174-81. 2011
    ..The impact of class-specific mutations on this rate of mutation replacement is uncertain...
  35. ncbi request reprint HIV-1 superinfection and viral diversity
    Kimber L Gross
    San Francisco Department of Public Health, San Francisco, California, USA
    AIDS 18:1513-20. 2004
    ..Animal models suggest that susceptibility to superinfection may be restricted to a short period of time after initial infection, possibly due to maturation of broad antiviral immune responses...
  36. ncbi request reprint Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia
    Steven G Deeks
    UCSF AIDS Program, University of California and San Francisco General Hospital, San Francisco, California 94110, USA
    AIDS 16:201-7. 2002
    ..Sustained elevations in CD4 cell counts commonly occur despite incomplete viral suppression with protease inhibitor-based antiretroviral therapy...
  37. pmc Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection
    Johan K Sandberg
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94141, USA
    J Virol 76:7528-34. 2002
    ..These data indicate that the key immunoregulatory NKT-cell compartment is compromised in HIV-1-infected patients...
  38. ncbi request reprint Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone
    Laura A Napolitano
    Gladstone Institute of Virology and Immunology, University of California at San Francisco, San Francisco, CA 94141, USA
    AIDS 16:1103-11. 2002
    ..To determine whether treatment with growth hormone (GH) enhances thymopoiesis in individuals infected with HIV-1...
  39. ncbi request reprint Seroconversion following nonoccupational postexposure prophylaxis against HIV
    Michelle E Roland
    Positive Health Program at San Francisco General Hospital, California, USA
    Clin Infect Dis 41:1507-13. 2005
    ..We sought to describe the occurrence and circumstances of HIV seroconversion following nonoccupational PEP...
  40. pmc Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis
    Robert M Grant
    Gladstone Institute of Virology and Immunology and University of California, San Francisco, USA
    Clin Infect Dis 50:S96-101. 2010
    ..Future implementation, if warranted, will be guided by the results of clinical trials in progress and engagement of communities exposed to HIV...
  41. pmc No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis
    Julia L Marcus
    Gladstone Institute of Virology and Immunology, San Francisco, California, United States of America University of California, Berkeley, California, United States of America
    PLoS ONE 8:e81997. 2013
    ..Self-reported sexual risk behavior decreased overall, but may be affected by reporting bias. We evaluated potential risk compensation using biomarkers of sexual risk behavior...
  42. ncbi request reprint HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy
    Jutta K Neuenburg
    Department of Neurology, University of California, San Francisco, USA
    J Acquir Immune Defic Syndr 31:171-7. 2002
    ..Although combination therapies decrease overall mortality and prevalence of CNS opportunistic infections, these therapies may be less active in preventing direct HIV-1 effects on the brain...
  43. ncbi request reprint Preexposure prophylaxis for HIV: unproven promise and potential pitfalls
    Albert Y Liu
    HIV Research Section, San Francisco Department of Public Health, San Francisco, Calif 94102, USA
    JAMA 296:863-5. 2006
  44. pmc Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1
    Oliver T Keppler
    Gladstone Institute of Virology and Immunology, School of Medicine, University of California at San Francisco, San Francisco, CA 94141, USA
    J Exp Med 195:719-36. 2002
    ..Transgenic rats also displayed a low-level plasma viremia early in infection. Thus, transgenic rats expressing the appropriate human receptor complex are promising candidates for a small animal model of HIV-1 infection...
  45. ncbi request reprint Real-time quantitation of HIV-1 p24 and SIV p27 using fluorescence-linked antigen quantification assays
    Matthew S Hayden
    Gladstone Institute of Virology and Immunology, San Francisco, CA, USA
    AIDS 17:629-31. 2003
    ..The speed, simplicity, and wide dynamic range of FIAQ assays makes them superior to enzyme-linked immunosorbent assays for many applications performed in research laboratories...
  46. pmc HIV drug-resistant strains as epidemiologic sentinels
    Maria S Sanchez
    University of California, Berkeley, California 94720, USA
    Emerg Infect Dis 12:191-7. 2006
    ..Our study highlights how drug resistance markers can be used as epidemiologic sentinels to devise public health solutions...
  47. ncbi request reprint Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls
    Vivian Levy
    Stanford University Division of Infectious Diseases, USA
    Clin Infect Dis 43:904-10. 2006
    ....
  48. ncbi request reprint Virological evaluation of the 'Ottawa case' indicates no evidence for HIV-1 superinfection
    Jonathan B Angel
    Ottawa Health Research Institute and The Ottawa Hospital, University of Ottawa, Ottawa, Canada
    AIDS 18:331-4. 2004
    ..Whether HIV-1 superinfection contributes to disease progression or the spread of drug-resistant HIV-1 remains unknown...
  49. ncbi request reprint Linking HIV and antiretroviral drug resistance surveillance in Peru: a model for a third-generation HIV sentinel surveillance
    Javier R Lama
    Asociacion Civil Impacta Salud y Educacion, Lima, Peru
    J Acquir Immune Defic Syndr 42:501-5. 2006
    ..HIV drug resistance surveillance is limited by recruitment and selection bias and by limited information regarding HIV incidence rates, secondary resistance, and treatment prevalence...
  50. pmc Randomized, controlled trial of therapy interruption in chronic HIV-1 infection
    Emmanouil Papasavvas
    The Wistar Institute, Philadelphia, Pennsylvania, USA
    PLoS Med 1:e64. 2004
    ....
  51. ncbi request reprint Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients
    Emmanouil Papasavvas
    Wistar Institute and the Philadelphia Field Initiating Group for HIV 1 Trials, Philadelphia, Pennsylvania, USA
    AIDS 17:2337-43. 2003
    ..To determine the effect of treatment interruptions (TI) on the evolution and persistence of drug-resistant viruses in chronically HIV-1-infected suppressed patients...
  52. ncbi request reprint A decrease in drug resistance levels of the HIV epidemic can be bad news
    Maria S Sanchez
    Department of Environmental Science, Policy and Management, University of California, Berkeley, CA 94720, USA
    Bull Math Biol 67:761-82. 2005
    ..Our results call for improved efforts to control the epidemic in developed nations, and highlight the usefulness of drug resistant strains as epidemiological markers...
  53. ncbi request reprint Detection of acute HIV infections
    Jeffrey D Klausner
    N Engl J Med 353:631-3; author reply 631-3. 2005
  54. ncbi request reprint High levels of adherence do not prevent accumulation of HIV drug resistance mutations
    David R Bangsberg
    Epidemiology and Prevention Interventions Center, Division of Infectious Diseases, San Francisco General Hospital, California, USA
    AIDS 17:1925-32. 2003
    ....
  55. ncbi request reprint Increased human T-lymphotropic virus type II proviral load following highly active retroviral therapy in HIV-coinfected patients
    Edward L Murphy
    J Acquir Immune Defic Syndr 33:655-6. 2003
  56. ncbi request reprint Chemoprophylaxis of HIV infection: moving forward with caution
    Robert M Grant
    J Infect Dis 194:874-6. 2006
  57. ncbi request reprint Drug resistance mutations in HIV-1
    RICHARD T D'AQUILA
    Vanderbilt University Medical Center, Nashville, TN, USA
    Top HIV Med 11:92-6. 2003
  58. ncbi request reprint Resistance testing in drug-naive HIV-infected patients: is it time?
    Frederick M Hecht
    Clin Infect Dis 41:1324-5. 2005
  59. pmc Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System
    Daniel R Kuritzkes
    Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Clin Microbiol 41:1594-9. 2003
    ..The TRUGENE HIV-1 Genotyping Kit and OpenGene DNA Sequencing System consistently generate highly accurate sequence data when tested with IMC-derived HIV and patient samples...
  60. ncbi request reprint Absence of HBV and HCV, HTLV-I and -II, and human herpes virus-8 activation after allogeneic RBC transfusion in patients with advanced HIV-1 infection
    David M Asmuth
    Department of Internal Medicine, Division of Infectious Diseases and Immunology, University of California Davis Medical Center, 4150 V Street, Suite 6200 PSSB, Sacramento, CA 95817, USA
    Transfusion 43:451-8. 2003
    ....
  61. ncbi request reprint Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure
    Stephen J Gange
    Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 41:68-74. 2006
    ....
  62. pmc Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo
    Erik S Zimmerman
    Division of Cellular Biology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
    J Virol 80:10407-18. 2006
    ..We report that infected cells in vivo display an aberrant cell cycle profile whereby a majority of cells have a 4N DNA content, consistent with the onset of G2 arrest...